Acinetobacter infections: a retrospective study to determine inhospital mortality rate and clinical factors associated with mortality [PDF]
Infection Prevention in Practice, 2019 Summary: A retrospective case series of acinetobacter infections at a tertiary hospital in Nairobi was conducted to determine the mortality rate and factors associated with mortality.
R.V. Patel +4 more
doaj +4 more sources
Prevalence, Risk Factors, and Outcome of Carbapenem-resistant Acinetobacter Infections in a Community Hospital in Madinah, Saudi Arabia [PDF]
Saudi Journal of Medicine and Medical SciencesBackground Acinetobacter is a Gram-negative bacterium that causes nosocomial infections, increasing healthcare costs, patient morbidity, and mortality.
Zied Gaifer +5 more
doaj +3 more sources
Perspectives in Clinical Research, 2016 Context: Acinetobacter infections are a major nosocomial infection causing epidemics of infection in the Intensive Care Units (ICU). Aims: This study estimates the clinical and economic outcomes of Acinetobacter infections and compares them with those of
Priyendu Asim +4 more
doaj +3 more sources
Acinetobacter Infections and Treatment
Journal of Pediatric Infection, 2014 Ozet Acinetobacter baumannii suslari ile olusan hastane enfeksiyonlari son yillarda morbidite ve mortalitenin onemli bir sebebi haline gelmistir. Klinik orneklerden en sik olarak izole edilen Acinetobacter turu olan A. baumannii virulansi dusuk bir bakteridir ve genellikle hastane kaynakli firsatci enfeksiyonlara neden olmaktadir. A.
Özlem Özgür, Necmi Aksaray
semanticscholar +4 more sources
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam. [PDF]
Front Microbiol, 2021 Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases.
Shapiro AB +4 more
europepmc +2 more sources
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections. [PDF]
Infect Dis Ther, 2017 Acinetobacter remains one of the most challenging pathogens in the field of infectious diseases owing primarily to the uniqueness and multiplicity of its resistance mechanisms.
Wenzler E +3 more
europepmc +2 more sources
Antimicrobial Agents and Chemotherapy, 2022 Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, but clinical data are limited.
Marco Falcone +2 more
exaly +2 more sources
Acinetobacter baumannii Infections in Times of COVID-19 Pandemic
Pathogens, 2021 The COVID-19 pandemic has generated an overuse of antimicrobials in critically ill patients. Acinetobacter baumannii frequently causes nosocomial infections, particularly in intensive care units (ICUs), where the incidence has increased over time.
Karyne Rangel +2 more
exaly +2 more sources
Acinetobacter infections: A growing threat in the hospital
Journal of Marine Medical Society, 2013 Acinetobacter baumannii is a Gram Negative coccobacilli implicated in causation of wide spectrum of nosocomial infections. Multidrug resistant Acinetobacter (MDR Acinetobacter) is emerging as an important cause of hospital acquired infections like ...
Ruby Chattopadhyay +4 more
doaj +2 more sources
Clinical Reflections of Acinetobacter Infections in Children in a Quaternary-Care Hospital: A Five-Year Single-Center Experience [PDF]
Turkish Archives of PediatricsObjective: This study aimed to determine the epidemiology of Acinetobacter species in the last 5 years, the clinical diseases caused by the pathogen, the possible risk factors for infection, and the resistance pattern of the microorganism in our ...
Ayşegül Elvan-Tüz +8 more
doaj +2 more sources